Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Jinxin Fertility

Request full access

Jinxin Fertility is a Chinese fertility services provider

Chengdu, ChinaFounded 2003Biotech & Life Sciences

About Jinxin Fertility

Jinxin Fertility Group operates as a provider of assisted reproductive services (ARS) with a significant presence in China and the United States. The company's origins in reproductive medicine trace back to 2003 with the formation of the Jinjiang IVF Center in Chengdu, which became part of the Jinxin group in 2010. This strategic focus was built upon the broader medical history of the Jinxin brand, which began operating hospitals in 1951. A pivotal milestone in the company's growth was its initial public offering on the Hong Kong Stock Exchange in June 2019.

The business model is centered on providing a comprehensive suite of fertility services, primarily in-vitro fertilization (IVF). The company generates revenue by offering these specialized medical services to individuals and couples. To expand its reach and service capabilities, Jinxin Fertility pursues a strategy of mergers and acquisitions. A key acquisition was HRC Management in December 2018, which provided a substantial entry into the U.S. market, particularly the West Coast. This international footprint allows the company to serve both domestic patients in China and the U.S., as well as international clients, including Chinese patients seeking services abroad. Further expansion includes a strategic partnership with PT Morula Indonesia announced in 2024 to tap into the Southeast Asian market.

Jinxin Fertility's services cover the full lifecycle of fertility treatment, from pre-pregnancy and IVF to prenatal, childbirth, and postpartum care. In addition to standard ARS, the company offers advanced options like molecular genetics services for pre-natal examination. Its network includes owned and managed hospitals and clinics in major Chinese cities like Chengdu, Shenzhen, and Wuhan, as well as in Hong Kong, Laos, and through HRC Fertility in the United States. The company emphasizes a 'doctor-partner mechanism', which has been in place since 2004, allowing many physicians to hold shares in the company, fostering talent retention and aligning interests. This approach, combined with collaborations like the one with the Keck School of Medicine of the University of Southern California for training IVF specialists, underpins its operational strategy.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
40.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Investment activity
1 company, latest Apr 2024
Capital deployed
$0
Preferred round
LATE VC

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES FOther financing Jun 2019 $150M $600M OrbiMed · Ally Bridge Group —
GROWTH EQUITY VCOther financing Oct 2018 — — Warburg Pincus —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Jinxin Fertility website traffic

Latest recorded traffic for Jinxin Fertility is 280 monthly website visits, down 42.9% over the last three months. Jinxin Fertility's team grew 0% over the past year.

Latest monthly visits280 3-month web change-42.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Jinxin Fertility in the Chengdu ecosystem

Live from Dealroom

The Jinxin Fertility office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States40%
🇨🇳 China40%
🇭🇰 Hong Kong20%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Jinxin Fertility on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Jinxin Fertility’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.